Aselizumab (HuDreg-55) is a humanized IgG4 monoclonal antibody (mAb) targeting L-selectin (CD62L), a cell adhesion molecule found on circulating neutrophils that directs cell migration through chemotaxis to injury sites. Notably, Aselizumab has been associated with an increased incidence of infections and leukopenia following trauma [1] [2].

Aselizumab 可与 HuDreg-55 轻链通过二硫键形成二聚体[1]。以 5-500 ng/mL 浓度，Aselizumab 在 25 分钟内有效阻断冷冻淋巴结切片中的 L-选择素依赖性淋巴细胞黏附于高内皮小静脉[3]。

Aselizumab（10 mg/kg；静脉注射；单次剂量）在恒河猴体内表现出12.0天的终末消除半衰期[3]。